nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—AOX1—Effects of Nitric Oxide—MB—sarcoma	0.111	0.531	CbGpPWpGaD
Brimonidine—AOX1—Effects of Nitric Oxide—HBA1—sarcoma	0.04	0.191	CbGpPWpGaD
Brimonidine—AOX1—Tryptophan metabolism—MDM2—sarcoma	0.00359	0.0172	CbGpPWpGaD
Brimonidine—Mental disorder—Vincristine—sarcoma	0.00316	0.00399	CcSEcCtD
Brimonidine—Arrhythmia—Mitoxantrone—sarcoma	0.00314	0.00396	CcSEcCtD
Brimonidine—Cough—Thiotepa—sarcoma	0.00309	0.0039	CcSEcCtD
Brimonidine—Erythema—Mitoxantrone—sarcoma	0.00306	0.00386	CcSEcCtD
Brimonidine—Hypertension—Thiotepa—sarcoma	0.00305	0.00386	CcSEcCtD
Brimonidine—Arthralgia—Thiotepa—sarcoma	0.00301	0.00381	CcSEcCtD
Brimonidine—Myalgia—Thiotepa—sarcoma	0.00301	0.00381	CcSEcCtD
Brimonidine—Dry eye—Epirubicin—sarcoma	0.00301	0.00381	CcSEcCtD
Brimonidine—Anxiety—Thiotepa—sarcoma	0.003	0.0038	CcSEcCtD
Brimonidine—Dysgeusia—Mitoxantrone—sarcoma	0.00299	0.00378	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.00299	0.00378	CcSEcCtD
Brimonidine—Myalgia—Dactinomycin—sarcoma	0.00299	0.00378	CcSEcCtD
Brimonidine—Dermatitis contact—Doxorubicin—sarcoma	0.00298	0.00377	CcSEcCtD
Brimonidine—Coma—Epirubicin—sarcoma	0.00298	0.00376	CcSEcCtD
Brimonidine—Discomfort—Dactinomycin—sarcoma	0.00295	0.00373	CcSEcCtD
Brimonidine—Vision blurred—Mitoxantrone—sarcoma	0.00288	0.00364	CcSEcCtD
Brimonidine—Infection—Thiotepa—sarcoma	0.00287	0.00363	CcSEcCtD
Brimonidine—Oedema—Dactinomycin—sarcoma	0.00287	0.00362	CcSEcCtD
Brimonidine—Infection—Dactinomycin—sarcoma	0.00285	0.0036	CcSEcCtD
Brimonidine—Abnormal vision—Epirubicin—sarcoma	0.00284	0.00359	CcSEcCtD
Brimonidine—Nervous system disorder—Thiotepa—sarcoma	0.00283	0.00358	CcSEcCtD
Brimonidine—Tachycardia—Thiotepa—sarcoma	0.00282	0.00356	CcSEcCtD
Brimonidine—Skin disorder—Thiotepa—sarcoma	0.0028	0.00355	CcSEcCtD
Brimonidine—Dry eye—Doxorubicin—sarcoma	0.00279	0.00352	CcSEcCtD
Brimonidine—Coma—Doxorubicin—sarcoma	0.00276	0.00348	CcSEcCtD
Brimonidine—Eye disorder—Etoposide—sarcoma	0.00273	0.00345	CcSEcCtD
Brimonidine—Diabetes mellitus—Epirubicin—sarcoma	0.00272	0.00344	CcSEcCtD
Brimonidine—Flushing—Etoposide—sarcoma	0.00271	0.00343	CcSEcCtD
Brimonidine—Cardiac disorder—Etoposide—sarcoma	0.00271	0.00343	CcSEcCtD
Brimonidine—Hypertension—Vincristine—sarcoma	0.00271	0.00342	CcSEcCtD
Brimonidine—Myalgia—Vincristine—sarcoma	0.00267	0.00338	CcSEcCtD
Brimonidine—Cough—Mitoxantrone—sarcoma	0.00267	0.00337	CcSEcCtD
Brimonidine—Angiopathy—Etoposide—sarcoma	0.00265	0.00335	CcSEcCtD
Brimonidine—Hypertension—Mitoxantrone—sarcoma	0.00264	0.00334	CcSEcCtD
Brimonidine—Immune system disorder—Etoposide—sarcoma	0.00264	0.00333	CcSEcCtD
Brimonidine—Mediastinal disorder—Etoposide—sarcoma	0.00263	0.00333	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Thiotepa—sarcoma	0.00263	0.00333	CcSEcCtD
Brimonidine—Abnormal vision—Doxorubicin—sarcoma	0.00263	0.00332	CcSEcCtD
Brimonidine—Eye pain—Epirubicin—sarcoma	0.00262	0.00331	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.00261	0.0033	CcSEcCtD
Brimonidine—Arthralgia—Mitoxantrone—sarcoma	0.0026	0.00329	CcSEcCtD
Brimonidine—Chest pain—Mitoxantrone—sarcoma	0.0026	0.00329	CcSEcCtD
Brimonidine—Myalgia—Mitoxantrone—sarcoma	0.0026	0.00329	CcSEcCtD
Brimonidine—Paraesthesia—Thiotepa—sarcoma	0.00259	0.00328	CcSEcCtD
Brimonidine—Anxiety—Mitoxantrone—sarcoma	0.00259	0.00328	CcSEcCtD
Brimonidine—Discomfort—Mitoxantrone—sarcoma	0.00257	0.00325	CcSEcCtD
Brimonidine—Somnolence—Thiotepa—sarcoma	0.00257	0.00325	CcSEcCtD
Brimonidine—Oedema—Vincristine—sarcoma	0.00256	0.00324	CcSEcCtD
Brimonidine—Infection—Vincristine—sarcoma	0.00254	0.00322	CcSEcCtD
Brimonidine—Dyspepsia—Thiotepa—sarcoma	0.00254	0.00321	CcSEcCtD
Brimonidine—Diabetes mellitus—Doxorubicin—sarcoma	0.00252	0.00318	CcSEcCtD
Brimonidine—Nervous system disorder—Vincristine—sarcoma	0.00251	0.00317	CcSEcCtD
Brimonidine—Oedema—Mitoxantrone—sarcoma	0.00249	0.00315	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Thiotepa—sarcoma	0.00249	0.00315	CcSEcCtD
Brimonidine—Fatigue—Thiotepa—sarcoma	0.00249	0.00315	CcSEcCtD
Brimonidine—Dysgeusia—Etoposide—sarcoma	0.00249	0.00315	CcSEcCtD
Brimonidine—Infection—Mitoxantrone—sarcoma	0.00248	0.00313	CcSEcCtD
Brimonidine—Fatigue—Dactinomycin—sarcoma	0.00247	0.00312	CcSEcCtD
Brimonidine—Pain—Thiotepa—sarcoma	0.00247	0.00312	CcSEcCtD
Brimonidine—Shock—Mitoxantrone—sarcoma	0.00245	0.0031	CcSEcCtD
Brimonidine—Pain—Dactinomycin—sarcoma	0.00245	0.0031	CcSEcCtD
Brimonidine—Tachycardia—Mitoxantrone—sarcoma	0.00243	0.00308	CcSEcCtD
Brimonidine—Eye pain—Doxorubicin—sarcoma	0.00242	0.00307	CcSEcCtD
Brimonidine—Skin disorder—Mitoxantrone—sarcoma	0.00242	0.00306	CcSEcCtD
Brimonidine—Lethargy—Epirubicin—sarcoma	0.00241	0.00305	CcSEcCtD
Brimonidine—Hypotension—Vincristine—sarcoma	0.00239	0.00303	CcSEcCtD
Brimonidine—Osteoarthritis—Epirubicin—sarcoma	0.00237	0.00299	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Vincristine—sarcoma	0.00233	0.00295	CcSEcCtD
Brimonidine—Hypotension—Mitoxantrone—sarcoma	0.00233	0.00295	CcSEcCtD
Brimonidine—Insomnia—Vincristine—sarcoma	0.00232	0.00293	CcSEcCtD
Brimonidine—Paraesthesia—Vincristine—sarcoma	0.0023	0.00291	CcSEcCtD
Brimonidine—Face oedema—Epirubicin—sarcoma	0.00228	0.00289	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.00227	0.00287	CcSEcCtD
Brimonidine—Paraesthesia—Mitoxantrone—sarcoma	0.00224	0.00283	CcSEcCtD
Brimonidine—Loss of consciousness—Etoposide—sarcoma	0.00223	0.00282	CcSEcCtD
Brimonidine—Lethargy—Doxorubicin—sarcoma	0.00223	0.00282	CcSEcCtD
Brimonidine—Dyspnoea—Mitoxantrone—sarcoma	0.00222	0.00281	CcSEcCtD
Brimonidine—Cough—Etoposide—sarcoma	0.00222	0.0028	CcSEcCtD
Brimonidine—Somnolence—Mitoxantrone—sarcoma	0.00222	0.0028	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Vincristine—sarcoma	0.00221	0.00279	CcSEcCtD
Brimonidine—Fatigue—Vincristine—sarcoma	0.00221	0.00279	CcSEcCtD
Brimonidine—Dyspepsia—Mitoxantrone—sarcoma	0.00219	0.00278	CcSEcCtD
Brimonidine—Hypertension—Etoposide—sarcoma	0.00219	0.00277	CcSEcCtD
Brimonidine—Pain—Vincristine—sarcoma	0.00219	0.00277	CcSEcCtD
Brimonidine—Osteoarthritis—Doxorubicin—sarcoma	0.00219	0.00277	CcSEcCtD
Brimonidine—Dry skin—Epirubicin—sarcoma	0.00217	0.00274	CcSEcCtD
Brimonidine—Chest pain—Etoposide—sarcoma	0.00216	0.00274	CcSEcCtD
Brimonidine—Fatigue—Mitoxantrone—sarcoma	0.00215	0.00272	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.00215	0.00272	CcSEcCtD
Brimonidine—Discomfort—Etoposide—sarcoma	0.00214	0.0027	CcSEcCtD
Brimonidine—Pain—Mitoxantrone—sarcoma	0.00213	0.0027	CcSEcCtD
Brimonidine—Hypersensitivity—Thiotepa—sarcoma	0.00213	0.00269	CcSEcCtD
Brimonidine—Nasopharyngitis—Epirubicin—sarcoma	0.00212	0.00267	CcSEcCtD
Brimonidine—Face oedema—Doxorubicin—sarcoma	0.00211	0.00267	CcSEcCtD
Brimonidine—Hypersensitivity—Dactinomycin—sarcoma	0.00211	0.00267	CcSEcCtD
Brimonidine—Asthenia—Thiotepa—sarcoma	0.00207	0.00262	CcSEcCtD
Brimonidine—Infection—Etoposide—sarcoma	0.00206	0.00261	CcSEcCtD
Brimonidine—Asthenia—Dactinomycin—sarcoma	0.00206	0.0026	CcSEcCtD
Brimonidine—Influenza—Epirubicin—sarcoma	0.00204	0.00259	CcSEcCtD
Brimonidine—Pruritus—Thiotepa—sarcoma	0.00204	0.00258	CcSEcCtD
Brimonidine—Tachycardia—Etoposide—sarcoma	0.00202	0.00256	CcSEcCtD
Brimonidine—Skin disorder—Etoposide—sarcoma	0.00201	0.00255	CcSEcCtD
Brimonidine—Dry skin—Doxorubicin—sarcoma	0.00201	0.00254	CcSEcCtD
Brimonidine—Bronchitis—Epirubicin—sarcoma	0.00197	0.00249	CcSEcCtD
Brimonidine—Nasopharyngitis—Doxorubicin—sarcoma	0.00196	0.00247	CcSEcCtD
Brimonidine—Hypotension—Etoposide—sarcoma	0.00194	0.00245	CcSEcCtD
Brimonidine—Dizziness—Thiotepa—sarcoma	0.00191	0.00241	CcSEcCtD
Brimonidine—Influenza—Doxorubicin—sarcoma	0.00189	0.00239	CcSEcCtD
Brimonidine—Hypersensitivity—Vincristine—sarcoma	0.00189	0.00239	CcSEcCtD
Brimonidine—Paraesthesia—Etoposide—sarcoma	0.00186	0.00235	CcSEcCtD
Brimonidine—Dyspnoea—Etoposide—sarcoma	0.00185	0.00234	CcSEcCtD
Brimonidine—Somnolence—Etoposide—sarcoma	0.00184	0.00233	CcSEcCtD
Brimonidine—Hypersensitivity—Mitoxantrone—sarcoma	0.00184	0.00232	CcSEcCtD
Brimonidine—Asthenia—Vincristine—sarcoma	0.00184	0.00232	CcSEcCtD
Brimonidine—Drowsiness—Epirubicin—sarcoma	0.00182	0.0023	CcSEcCtD
Brimonidine—Rash—Thiotepa—sarcoma	0.00182	0.0023	CcSEcCtD
Brimonidine—Bronchitis—Doxorubicin—sarcoma	0.00182	0.0023	CcSEcCtD
Brimonidine—Dermatitis—Thiotepa—sarcoma	0.00182	0.0023	CcSEcCtD
Brimonidine—Headache—Thiotepa—sarcoma	0.00181	0.00229	CcSEcCtD
Brimonidine—Rash—Dactinomycin—sarcoma	0.00181	0.00228	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Etoposide—sarcoma	0.00179	0.00226	CcSEcCtD
Brimonidine—Asthenia—Mitoxantrone—sarcoma	0.00179	0.00226	CcSEcCtD
Brimonidine—Fatigue—Etoposide—sarcoma	0.00179	0.00226	CcSEcCtD
Brimonidine—Pain—Etoposide—sarcoma	0.00177	0.00224	CcSEcCtD
Brimonidine—Conjunctivitis—Epirubicin—sarcoma	0.00177	0.00224	CcSEcCtD
Brimonidine—Nausea—Thiotepa—sarcoma	0.00172	0.00217	CcSEcCtD
Brimonidine—Sinusitis—Epirubicin—sarcoma	0.00171	0.00216	CcSEcCtD
Brimonidine—Nausea—Dactinomycin—sarcoma	0.0017	0.00215	CcSEcCtD
Brimonidine—Dizziness—Vincristine—sarcoma	0.00169	0.00214	CcSEcCtD
Brimonidine—Drowsiness—Doxorubicin—sarcoma	0.00169	0.00213	CcSEcCtD
Brimonidine—Bradycardia—Epirubicin—sarcoma	0.00167	0.00211	CcSEcCtD
Brimonidine—Rhinitis—Epirubicin—sarcoma	0.00164	0.00207	CcSEcCtD
Brimonidine—Conjunctivitis—Doxorubicin—sarcoma	0.00164	0.00207	CcSEcCtD
Brimonidine—Pharyngitis—Epirubicin—sarcoma	0.00162	0.00205	CcSEcCtD
Brimonidine—Rash—Vincristine—sarcoma	0.00161	0.00204	CcSEcCtD
Brimonidine—Dermatitis—Vincristine—sarcoma	0.00161	0.00204	CcSEcCtD
Brimonidine—Headache—Vincristine—sarcoma	0.0016	0.00203	CcSEcCtD
Brimonidine—Sinusitis—Doxorubicin—sarcoma	0.00158	0.002	CcSEcCtD
Brimonidine—Visual impairment—Epirubicin—sarcoma	0.00158	0.00199	CcSEcCtD
Brimonidine—Rash—Mitoxantrone—sarcoma	0.00157	0.00199	CcSEcCtD
Brimonidine—Dermatitis—Mitoxantrone—sarcoma	0.00157	0.00199	CcSEcCtD
Brimonidine—Headache—Mitoxantrone—sarcoma	0.00156	0.00198	CcSEcCtD
Brimonidine—ADRA2B—Platelet Aggregation (Plug Formation)—SRC—sarcoma	0.00156	0.00744	CbGpPWpGaD
Brimonidine—Bradycardia—Doxorubicin—sarcoma	0.00154	0.00195	CcSEcCtD
Brimonidine—Eye disorder—Epirubicin—sarcoma	0.00153	0.00193	CcSEcCtD
Brimonidine—Hypersensitivity—Etoposide—sarcoma	0.00153	0.00193	CcSEcCtD
Brimonidine—Nausea—Vincristine—sarcoma	0.00152	0.00192	CcSEcCtD
Brimonidine—Flushing—Epirubicin—sarcoma	0.00152	0.00192	CcSEcCtD
Brimonidine—Cardiac disorder—Epirubicin—sarcoma	0.00152	0.00192	CcSEcCtD
Brimonidine—Rhinitis—Doxorubicin—sarcoma	0.00152	0.00192	CcSEcCtD
Brimonidine—Pharyngitis—Doxorubicin—sarcoma	0.0015	0.0019	CcSEcCtD
Brimonidine—Asthenia—Etoposide—sarcoma	0.00149	0.00188	CcSEcCtD
Brimonidine—Angiopathy—Epirubicin—sarcoma	0.00148	0.00188	CcSEcCtD
Brimonidine—Nausea—Mitoxantrone—sarcoma	0.00148	0.00187	CcSEcCtD
Brimonidine—Immune system disorder—Epirubicin—sarcoma	0.00148	0.00187	CcSEcCtD
Brimonidine—Mediastinal disorder—Epirubicin—sarcoma	0.00147	0.00186	CcSEcCtD
Brimonidine—Pruritus—Etoposide—sarcoma	0.00147	0.00186	CcSEcCtD
Brimonidine—Arrhythmia—Epirubicin—sarcoma	0.00146	0.00185	CcSEcCtD
Brimonidine—Visual impairment—Doxorubicin—sarcoma	0.00146	0.00185	CcSEcCtD
Brimonidine—ADRA2C—Platelet Aggregation (Plug Formation)—SRC—sarcoma	0.00145	0.00695	CbGpPWpGaD
Brimonidine—Mental disorder—Epirubicin—sarcoma	0.00143	0.00181	CcSEcCtD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—VEGFC—sarcoma	0.00143	0.00683	CbGpPWpGaD
Brimonidine—Erythema—Epirubicin—sarcoma	0.00142	0.0018	CcSEcCtD
Brimonidine—Eye disorder—Doxorubicin—sarcoma	0.00142	0.00179	CcSEcCtD
Brimonidine—Cardiac disorder—Doxorubicin—sarcoma	0.00141	0.00178	CcSEcCtD
Brimonidine—Flushing—Doxorubicin—sarcoma	0.00141	0.00178	CcSEcCtD
Brimonidine—Dysgeusia—Epirubicin—sarcoma	0.0014	0.00176	CcSEcCtD
Brimonidine—Angiopathy—Doxorubicin—sarcoma	0.00137	0.00174	CcSEcCtD
Brimonidine—Dizziness—Etoposide—sarcoma	0.00137	0.00173	CcSEcCtD
Brimonidine—Immune system disorder—Doxorubicin—sarcoma	0.00137	0.00173	CcSEcCtD
Brimonidine—Mediastinal disorder—Doxorubicin—sarcoma	0.00136	0.00173	CcSEcCtD
Brimonidine—Arrhythmia—Doxorubicin—sarcoma	0.00135	0.00171	CcSEcCtD
Brimonidine—Vision blurred—Epirubicin—sarcoma	0.00134	0.0017	CcSEcCtD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—VEGFC—sarcoma	0.00133	0.00638	CbGpPWpGaD
Brimonidine—Mental disorder—Doxorubicin—sarcoma	0.00133	0.00168	CcSEcCtD
Brimonidine—Erythema—Doxorubicin—sarcoma	0.00132	0.00167	CcSEcCtD
Brimonidine—Rash—Etoposide—sarcoma	0.00131	0.00165	CcSEcCtD
Brimonidine—Dermatitis—Etoposide—sarcoma	0.00131	0.00165	CcSEcCtD
Brimonidine—Headache—Etoposide—sarcoma	0.0013	0.00164	CcSEcCtD
Brimonidine—Dysgeusia—Doxorubicin—sarcoma	0.00129	0.00163	CcSEcCtD
Brimonidine—Syncope—Epirubicin—sarcoma	0.00128	0.00162	CcSEcCtD
Brimonidine—Palpitations—Epirubicin—sarcoma	0.00126	0.00159	CcSEcCtD
Brimonidine—Loss of consciousness—Epirubicin—sarcoma	0.00125	0.00158	CcSEcCtD
Brimonidine—Cough—Epirubicin—sarcoma	0.00124	0.00157	CcSEcCtD
Brimonidine—Vision blurred—Doxorubicin—sarcoma	0.00124	0.00157	CcSEcCtD
Brimonidine—Nausea—Etoposide—sarcoma	0.00123	0.00156	CcSEcCtD
Brimonidine—Hypertension—Epirubicin—sarcoma	0.00123	0.00156	CcSEcCtD
Brimonidine—Arthralgia—Epirubicin—sarcoma	0.00121	0.00153	CcSEcCtD
Brimonidine—Chest pain—Epirubicin—sarcoma	0.00121	0.00153	CcSEcCtD
Brimonidine—Myalgia—Epirubicin—sarcoma	0.00121	0.00153	CcSEcCtD
Brimonidine—Anxiety—Epirubicin—sarcoma	0.00121	0.00153	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.0012	0.00152	CcSEcCtD
Brimonidine—Discomfort—Epirubicin—sarcoma	0.0012	0.00152	CcSEcCtD
Brimonidine—Dry mouth—Epirubicin—sarcoma	0.00119	0.0015	CcSEcCtD
Brimonidine—Syncope—Doxorubicin—sarcoma	0.00118	0.00149	CcSEcCtD
Brimonidine—ADRA2A—Platelet Aggregation (Plug Formation)—SRC—sarcoma	0.00118	0.00564	CbGpPWpGaD
Brimonidine—Palpitations—Doxorubicin—sarcoma	0.00116	0.00147	CcSEcCtD
Brimonidine—Oedema—Epirubicin—sarcoma	0.00116	0.00147	CcSEcCtD
Brimonidine—Loss of consciousness—Doxorubicin—sarcoma	0.00116	0.00146	CcSEcCtD
Brimonidine—Infection—Epirubicin—sarcoma	0.00116	0.00146	CcSEcCtD
Brimonidine—Cough—Doxorubicin—sarcoma	0.00115	0.00145	CcSEcCtD
Brimonidine—Shock—Epirubicin—sarcoma	0.00114	0.00145	CcSEcCtD
Brimonidine—Nervous system disorder—Epirubicin—sarcoma	0.00114	0.00144	CcSEcCtD
Brimonidine—Hypertension—Doxorubicin—sarcoma	0.00114	0.00144	CcSEcCtD
Brimonidine—Tachycardia—Epirubicin—sarcoma	0.00113	0.00143	CcSEcCtD
Brimonidine—Skin disorder—Epirubicin—sarcoma	0.00113	0.00143	CcSEcCtD
Brimonidine—Arthralgia—Doxorubicin—sarcoma	0.00112	0.00142	CcSEcCtD
Brimonidine—Chest pain—Doxorubicin—sarcoma	0.00112	0.00142	CcSEcCtD
Brimonidine—Myalgia—Doxorubicin—sarcoma	0.00112	0.00142	CcSEcCtD
Brimonidine—Anxiety—Doxorubicin—sarcoma	0.00112	0.00141	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.00111	0.00141	CcSEcCtD
Brimonidine—Discomfort—Doxorubicin—sarcoma	0.00111	0.0014	CcSEcCtD
Brimonidine—Dry mouth—Doxorubicin—sarcoma	0.0011	0.00139	CcSEcCtD
Brimonidine—Hypotension—Epirubicin—sarcoma	0.00109	0.00137	CcSEcCtD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—VEGFC—sarcoma	0.00108	0.00518	CbGpPWpGaD
Brimonidine—Oedema—Doxorubicin—sarcoma	0.00108	0.00136	CcSEcCtD
Brimonidine—Infection—Doxorubicin—sarcoma	0.00107	0.00135	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Epirubicin—sarcoma	0.00106	0.00134	CcSEcCtD
Brimonidine—Shock—Doxorubicin—sarcoma	0.00106	0.00134	CcSEcCtD
Brimonidine—Nervous system disorder—Doxorubicin—sarcoma	0.00105	0.00133	CcSEcCtD
Brimonidine—Insomnia—Epirubicin—sarcoma	0.00105	0.00133	CcSEcCtD
Brimonidine—Tachycardia—Doxorubicin—sarcoma	0.00105	0.00133	CcSEcCtD
Brimonidine—Skin disorder—Doxorubicin—sarcoma	0.00104	0.00132	CcSEcCtD
Brimonidine—Paraesthesia—Epirubicin—sarcoma	0.00104	0.00132	CcSEcCtD
Brimonidine—Dyspnoea—Epirubicin—sarcoma	0.00104	0.00131	CcSEcCtD
Brimonidine—Somnolence—Epirubicin—sarcoma	0.00103	0.00131	CcSEcCtD
Brimonidine—ADRA2B—G alpha (i) signalling events—CXCR4—sarcoma	0.00103	0.00491	CbGpPWpGaD
Brimonidine—Dyspepsia—Epirubicin—sarcoma	0.00102	0.00129	CcSEcCtD
Brimonidine—Hypotension—Doxorubicin—sarcoma	0.00101	0.00127	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Epirubicin—sarcoma	0.001	0.00127	CcSEcCtD
Brimonidine—Fatigue—Epirubicin—sarcoma	0.001	0.00127	CcSEcCtD
Brimonidine—ADRA2B—Hemostasis—TEK—sarcoma	0.001	0.00479	CbGpPWpGaD
Brimonidine—Pain—Epirubicin—sarcoma	0.000994	0.00126	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.00098	0.00124	CcSEcCtD
Brimonidine—Insomnia—Doxorubicin—sarcoma	0.000973	0.00123	CcSEcCtD
Brimonidine—Paraesthesia—Doxorubicin—sarcoma	0.000966	0.00122	CcSEcCtD
Brimonidine—Dyspnoea—Doxorubicin—sarcoma	0.000959	0.00121	CcSEcCtD
Brimonidine—ADRA2C—G alpha (i) signalling events—CXCR4—sarcoma	0.000958	0.00458	CbGpPWpGaD
Brimonidine—Somnolence—Doxorubicin—sarcoma	0.000956	0.00121	CcSEcCtD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—CXCR4—sarcoma	0.000952	0.00455	CbGpPWpGaD
Brimonidine—Dyspepsia—Doxorubicin—sarcoma	0.000947	0.0012	CcSEcCtD
Brimonidine—ADRA2C—Hemostasis—TEK—sarcoma	0.000936	0.00448	CbGpPWpGaD
Brimonidine—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000929	0.00117	CcSEcCtD
Brimonidine—Fatigue—Doxorubicin—sarcoma	0.000927	0.00117	CcSEcCtD
Brimonidine—Pain—Doxorubicin—sarcoma	0.00092	0.00116	CcSEcCtD
Brimonidine—ADRA2B—Hemostasis—ANGPT2—sarcoma	0.000917	0.00438	CbGpPWpGaD
Brimonidine—AOX1—Disease—TLE1—sarcoma	0.000904	0.00432	CbGpPWpGaD
Brimonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—CXCR4—sarcoma	0.000889	0.00425	CbGpPWpGaD
Brimonidine—Hypersensitivity—Epirubicin—sarcoma	0.000857	0.00108	CcSEcCtD
Brimonidine—ADRA2C—Hemostasis—ANGPT2—sarcoma	0.000856	0.0041	CbGpPWpGaD
Brimonidine—Asthenia—Epirubicin—sarcoma	0.000834	0.00105	CcSEcCtD
Brimonidine—Pruritus—Epirubicin—sarcoma	0.000823	0.00104	CcSEcCtD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCR4—sarcoma	0.000816	0.0039	CbGpPWpGaD
Brimonidine—AOX1—Disease—NPM1—sarcoma	0.000816	0.0039	CbGpPWpGaD
Brimonidine—Hypersensitivity—Doxorubicin—sarcoma	0.000793	0.001	CcSEcCtD
Brimonidine—ADRA2A—G alpha (i) signalling events—CXCR4—sarcoma	0.000778	0.00372	CbGpPWpGaD
Brimonidine—Asthenia—Doxorubicin—sarcoma	0.000772	0.000976	CcSEcCtD
Brimonidine—Dizziness—Epirubicin—sarcoma	0.000769	0.000972	CcSEcCtD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCR4—sarcoma	0.000762	0.00364	CbGpPWpGaD
Brimonidine—Pruritus—Doxorubicin—sarcoma	0.000761	0.000962	CcSEcCtD
Brimonidine—ADRA2A—Hemostasis—TEK—sarcoma	0.000761	0.00364	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—VEGFC—sarcoma	0.000736	0.00352	CbGpPWpGaD
Brimonidine—Rash—Epirubicin—sarcoma	0.000733	0.000927	CcSEcCtD
Brimonidine—Dermatitis—Epirubicin—sarcoma	0.000732	0.000926	CcSEcCtD
Brimonidine—Headache—Epirubicin—sarcoma	0.000728	0.000921	CcSEcCtD
Brimonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—CXCR4—sarcoma	0.000722	0.00345	CbGpPWpGaD
Brimonidine—Dizziness—Doxorubicin—sarcoma	0.000711	0.000899	CcSEcCtD
Brimonidine—AOX1—Disease—ENO2—sarcoma	0.000707	0.00338	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—ANGPT2—sarcoma	0.000696	0.00333	CbGpPWpGaD
Brimonidine—Nausea—Epirubicin—sarcoma	0.000691	0.000873	CcSEcCtD
Brimonidine—ADRA2C—Hemostasis—VEGFC—sarcoma	0.000687	0.00329	CbGpPWpGaD
Brimonidine—Rash—Doxorubicin—sarcoma	0.000678	0.000858	CcSEcCtD
Brimonidine—Dermatitis—Doxorubicin—sarcoma	0.000678	0.000857	CcSEcCtD
Brimonidine—Headache—Doxorubicin—sarcoma	0.000674	0.000852	CcSEcCtD
Brimonidine—Nausea—Doxorubicin—sarcoma	0.000639	0.000808	CcSEcCtD
Brimonidine—ADRA2B—GPCR ligand binding—CXCR4—sarcoma	0.000621	0.00297	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCR4—sarcoma	0.000619	0.00296	CbGpPWpGaD
Brimonidine—AOX1—Disease—PLCG1—sarcoma	0.000599	0.00287	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—ENO2—sarcoma	0.000592	0.00283	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—HBA1—sarcoma	0.000588	0.00281	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—CXCR4—sarcoma	0.00058	0.00277	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—PLCG1—sarcoma	0.000578	0.00276	CbGpPWpGaD
Brimonidine—AOX1—Disease—CXCR4—sarcoma	0.000576	0.00275	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—VEGFC—sarcoma	0.000558	0.00267	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—PLCG1—sarcoma	0.00054	0.00258	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PLCG1—sarcoma	0.000502	0.0024	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—CXCR4—sarcoma	0.000471	0.00225	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—PLCG1—sarcoma	0.000439	0.0021	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—IL2—sarcoma	0.000427	0.00204	CbGpPWpGaD
Brimonidine—AOX1—Disease—FOXO1—sarcoma	0.000425	0.00203	CbGpPWpGaD
Brimonidine—AOX1—Disease—PDGFRB—sarcoma	0.000425	0.00203	CbGpPWpGaD
Brimonidine—AOX1—Disease—PDGFRA—sarcoma	0.000418	0.002	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—IL2—sarcoma	0.000399	0.00191	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—SRC—sarcoma	0.000372	0.00178	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—sarcoma	0.000363	0.00173	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—CXCR4—sarcoma	0.000351	0.00168	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—SRC—sarcoma	0.000348	0.00166	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—VEGFA—sarcoma	0.000339	0.00162	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—CXCR4—sarcoma	0.000328	0.00157	CbGpPWpGaD
Brimonidine—AOX1—Disease—KIT—sarcoma	0.000324	0.00155	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—IL2—sarcoma	0.000324	0.00155	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CXCR4—sarcoma	0.000319	0.00152	CbGpPWpGaD
Brimonidine—AOX1—Disease—CREB1—sarcoma	0.000309	0.00148	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CXCR4—sarcoma	0.000298	0.00142	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TLE1—sarcoma	0.000296	0.00141	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—SRC—sarcoma	0.000282	0.00135	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TLE1—sarcoma	0.000276	0.00132	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—sarcoma	0.000275	0.00132	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CXCR4—sarcoma	0.000266	0.00127	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ENO2—sarcoma	0.000258	0.00123	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—HBA1—sarcoma	0.000256	0.00123	CbGpPWpGaD
Brimonidine—AOX1—Disease—MDM2—sarcoma	0.000255	0.00122	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—VEGFC—sarcoma	0.000249	0.00119	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CXCR4—sarcoma	0.000242	0.00116	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—VEGFC—sarcoma	0.000233	0.00111	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TLE1—sarcoma	0.000224	0.00107	CbGpPWpGaD
Brimonidine—AOX1—Disease—CTNNB1—sarcoma	0.00022	0.00105	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—IL2—sarcoma	0.00022	0.00105	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PLCG1—sarcoma	0.000219	0.00105	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ENO2—sarcoma	0.00021	0.001	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—HBA1—sarcoma	0.000208	0.000996	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—IL2—sarcoma	0.000205	0.000983	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FLT1—sarcoma	0.000199	0.000954	CbGpPWpGaD
Brimonidine—AOX1—Disease—SRC—sarcoma	0.000199	0.000952	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PLCG1—sarcoma	0.000196	0.000937	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—SRC—sarcoma	0.000192	0.000918	CbGpPWpGaD
Brimonidine—AOX1—Disease—NRAS—sarcoma	0.000191	0.000916	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—VEGFC—sarcoma	0.000189	0.000905	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CXCR4—sarcoma	0.000188	0.000901	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—VEGFA—sarcoma	0.000187	0.000894	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FLT1—sarcoma	0.000186	0.000891	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ATF1—sarcoma	0.000186	0.00089	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—NRAS—sarcoma	0.000185	0.000883	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PLCG1—sarcoma	0.000183	0.000876	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—SRC—sarcoma	0.000179	0.000857	CbGpPWpGaD
Brimonidine—AOX1—Disease—MYC—sarcoma	0.000178	0.000853	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PLCG1—sarcoma	0.000178	0.000851	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CXCR4—sarcoma	0.000176	0.000841	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—VEGFA—sarcoma	0.000175	0.000835	CbGpPWpGaD
Brimonidine—AOX1—Disease—EGFR—sarcoma	0.000174	0.000834	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ATF1—sarcoma	0.000174	0.000832	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—NRAS—sarcoma	0.000172	0.000825	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CREB1—sarcoma	0.000171	0.000817	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—IL2—sarcoma	0.000167	0.000798	CbGpPWpGaD
Brimonidine—AOX1—Disease—KRAS—sarcoma	0.000165	0.000788	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CREB1—sarcoma	0.000159	0.000763	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—KRAS—sarcoma	0.000159	0.00076	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FLT1—sarcoma	0.000151	0.000724	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PLCG1—sarcoma	0.000149	0.000711	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—KRAS—sarcoma	0.000148	0.00071	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IGF1R—sarcoma	0.000146	0.000699	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—SRC—sarcoma	0.000146	0.000696	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CXCR4—sarcoma	0.000143	0.000683	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—VEGFA—sarcoma	0.000142	0.000678	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ATF1—sarcoma	0.000141	0.000676	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—TP53—sarcoma	0.000141	0.000676	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—NRAS—sarcoma	0.00014	0.00067	CbGpPWpGaD
Brimonidine—AOX1—Disease—HRAS—sarcoma	0.00014	0.00067	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—FOXO1—sarcoma	0.000139	0.000665	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—IL2—sarcoma	0.000139	0.000665	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PDGFRB—sarcoma	0.000139	0.000664	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PDGFRA—sarcoma	0.000137	0.000654	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IGF1R—sarcoma	0.000136	0.000653	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—HRAS—sarcoma	0.000135	0.000646	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—TP53—sarcoma	0.000132	0.000631	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—FOXO1—sarcoma	0.00013	0.000621	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—IL2—sarcoma	0.00013	0.000621	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PDGFRB—sarcoma	0.00013	0.00062	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CREB1—sarcoma	0.00013	0.00062	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PDGFRA—sarcoma	0.000128	0.000611	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—IL2—sarcoma	0.000126	0.000604	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—HRAS—sarcoma	0.000126	0.000603	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—KRAS—sarcoma	0.000121	0.000577	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—IL2—sarcoma	0.000118	0.000564	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KDR—sarcoma	0.000115	0.00055	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IGF1R—sarcoma	0.000111	0.00053	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KDR—sarcoma	0.000107	0.000514	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TP53—sarcoma	0.000107	0.000513	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KIT—sarcoma	0.000106	0.000507	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—NRAS—sarcoma	0.000106	0.000507	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—FOXO1—sarcoma	0.000106	0.000505	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—IL2—sarcoma	0.000105	0.000504	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PDGFRB—sarcoma	0.000105	0.000504	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PDGFRA—sarcoma	0.000104	0.000496	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—HRAS—sarcoma	0.000102	0.00049	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CREB1—sarcoma	0.000101	0.000482	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KIT—sarcoma	9.9e-05	0.000473	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—NRAS—sarcoma	9.9e-05	0.000473	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—EGFR—sarcoma	9.65e-05	0.000462	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—IL2—sarcoma	9.58e-05	0.000458	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CREB1—sarcoma	9.42e-05	0.000451	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—KRAS—sarcoma	9.12e-05	0.000436	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—EGFR—sarcoma	9.02e-05	0.000431	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KDR—sarcoma	8.73e-05	0.000417	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—KRAS—sarcoma	8.52e-05	0.000407	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MDM2—sarcoma	8.35e-05	0.000399	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KIT—sarcoma	8.04e-05	0.000385	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—NRAS—sarcoma	8.04e-05	0.000385	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MDM2—sarcoma	7.8e-05	0.000373	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—HRAS—sarcoma	7.75e-05	0.000371	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CREB1—sarcoma	7.65e-05	0.000366	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—IL2—sarcoma	7.46e-05	0.000357	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—EGFR—sarcoma	7.32e-05	0.00035	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCND1—sarcoma	7.27e-05	0.000348	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—JUN—sarcoma	7.25e-05	0.000347	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—HRAS—sarcoma	7.24e-05	0.000346	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CTNNB1—sarcoma	7.2e-05	0.000344	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—IL2—sarcoma	6.97e-05	0.000333	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—KRAS—sarcoma	6.92e-05	0.000331	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCND1—sarcoma	6.79e-05	0.000325	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—JUN—sarcoma	6.78e-05	0.000324	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CTNNB1—sarcoma	6.72e-05	0.000322	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SRC—sarcoma	6.51e-05	0.000311	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—VEGFA—sarcoma	6.34e-05	0.000303	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MDM2—sarcoma	6.33e-05	0.000303	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NRAS—sarcoma	6.26e-05	0.000299	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SRC—sarcoma	6.08e-05	0.000291	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—VEGFA—sarcoma	5.92e-05	0.000283	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—HRAS—sarcoma	5.88e-05	0.000281	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NRAS—sarcoma	5.85e-05	0.00028	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MYC—sarcoma	5.83e-05	0.000279	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EGFR—sarcoma	5.7e-05	0.000273	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IL2—sarcoma	5.66e-05	0.000271	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCND1—sarcoma	5.52e-05	0.000264	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—JUN—sarcoma	5.5e-05	0.000263	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CTNNB1—sarcoma	5.46e-05	0.000261	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MYC—sarcoma	5.45e-05	0.00026	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KRAS—sarcoma	5.39e-05	0.000258	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EGFR—sarcoma	5.33e-05	0.000255	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KRAS—sarcoma	5.03e-05	0.000241	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SRC—sarcoma	4.94e-05	0.000236	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—VEGFA—sarcoma	4.81e-05	0.00023	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TP53—sarcoma	4.79e-05	0.000229	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NRAS—sarcoma	4.75e-05	0.000227	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HRAS—sarcoma	4.58e-05	0.000219	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TP53—sarcoma	4.47e-05	0.000214	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MYC—sarcoma	4.42e-05	0.000212	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EGFR—sarcoma	4.33e-05	0.000207	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HRAS—sarcoma	4.28e-05	0.000205	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KRAS—sarcoma	4.09e-05	0.000195	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TP53—sarcoma	3.63e-05	0.000174	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HRAS—sarcoma	3.47e-05	0.000166	CbGpPWpGaD
